Curesponse

Company Overview

Snapshot

Founded in November 2017 by Guy Neev and Seth Salpeter, Curesponse operates with 11–50 employees. The company has secured funding across two rounds from three investors. In February 2023, Curesponse announced that Clalit Health Services, the largest Israeli HMO, would provide commercial coverage for its cResponse test.

Business overview

Curesponse is at the forefront of personalized cancer medicine, developing advanced prediction capabilities that extend beyond genomics. The company’s core technology, cResponse, is a combined Genomic-Functional assay designed to assess how cancer treatments will affect a patient’s tumor cells within their native tumor microenvironment. This test integrates genomic profiling to prioritize therapies and then functionally tests selected drugs and drug combinations on the patient’s tumor, preserving its original composition and 3D structure. Curesponse serves the healthcare and life sciences sectors, specifically targeting pharmaceuticals and oncology, to provide highly accurate empirical analysis for treatment effectiveness.

Strategic signal

In May 2023, Curesponse presented positive preliminary clinical results from a multi-center UK study at the AACR Meeting in Orlando, Florida. This signals significant progress in validating the clinical efficacy of its cResponse platform, demonstrating its potential to improve treatment outcomes in precision oncology and attracting further interest from the medical community and potential partners.

Company Intelligence Q&A

What is Curesponse's primary product?

Curesponse's primary product is cResponse, a combined Genomic-Functional assay designed to provide personalized cancer treatment predictions by testing drug effectiveness on a patient's tumor cells in their native environment.

When was Curesponse founded and by whom?

Curesponse was founded in November 2017 by co-founders Guy Neev and Seth Salpeter.

What was a significant commercial milestone for Curesponse in 2023?

In February 2023, Curesponse announced that Clalit Health Services, the largest Israeli HMO, would provide commercial coverage for the cResponse test, indicating significant market adoption and validation.

What clinical results did Curesponse present in May 2023?

In May 2023, Curesponse presented positive preliminary clinical results from a multi-center UK study at the AACR Meeting in Orlando, Florida, demonstrating the efficacy of its precision oncology platform.

Which investors participated in Curesponse's June 2020 funding round?

In June 2020, Curesponse secured funding from aMoon Fund and NCL Technology Ventures.